Exubera Gone, But Not Forgotten: FDA Imposes REMS, Mandates Trials
This article was originally published in RPM Report
Executive Summary
Pfizer is no longer marketing inhaled insulin, but the regulatory work continues. FDA makes clear that any future inhaled insulin products will need a risk management plan and mandatory post-marketing studies.